Anaptysbio (ANAB) Non Operating Income (2016 - 2026)
Anaptysbio posted quarterly Non Operating Income of -$1000.0 for Q1 2026, down 100.05% year-on-year from $1.9 million in Q1 2025, and down 100.0% on a QoQ basis from $49.2 million in Q4 2025.
Anaptysbio (ANAB) has 11 years of Non Operating Income data on file, last reported at -$1000.0 in Q1 2026.
- For the quarter ending Q1 2026, Non Operating Income fell 100.05% year-over-year to -$1000.0; the trailing twelve-month figure through Mar 2026 stood at $52.7 million (up 615.68% YoY), and the FY2025 full-year result was $5.4 million, up 117.93% from the prior year.
- Non Operating Income for Q1 2026 stood at -$1000.0, down from $49.2 million in the prior quarter.
- Across five years, Non Operating Income topped out at $49.2 million in Q4 2025 and bottomed at -$12.1 million in Q4 2024.
- The 5-year median for Non Operating Income is -$1000.0 (2026), against an average of $2.2 million.
- The widest annual swing landed in 2023, when Non Operating Income jumped 4866.67%; it then sank 605900.0% in 2024.
- A 5-year view of Non Operating Income shows it stood at -$4000.0 in 2022, then surged by 50.0% to -$2000.0 in 2023, then tumbled by 605900.0% to -$12.1 million in 2024, then soared by 505.84% to $49.2 million in 2025, then slumped by 100.0% to -$1000.0 in 2026.
- The last three Non Operating Income figures came in at -$1000.0 (Q1 2026), $49.2 million (Q4 2025), and $3.5 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 444,000.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 201.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | -46.98 Mn |
| 10 | Anaptysbio | 1.60 Bn | 1.31 Bn | - | -1,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1,000.00 |
| Dec 31, 2025 | 49.19 Mn |
| Jun 30, 2025 | 3.53 Mn |
| Mar 31, 2025 | 1.90 Mn |
| Dec 31, 2024 | -12.12 Mn |
| Sep 30, 2024 | -5,000.00 |
| Mar 31, 2024 | -1.74 Mn |
| Dec 31, 2023 | -2,000.00 |
| Sep 30, 2023 | 1,000.00 |
| Jun 30, 2023 | 298,000.00 |
| Mar 31, 2023 | 146,000.00 |
| Dec 31, 2022 | -4,000.00 |
| Sep 30, 2022 | -3.87 Mn |
| Jun 30, 2022 | 6,000.00 |
| Mar 31, 2022 | -4.51 Mn |
| Dec 31, 2021 | -362,000.00 |
| Sep 30, 2021 | 33,000.00 |
| Mar 31, 2021 | 198,000.00 |
| Dec 31, 2020 | -75,000.00 |
| Sep 30, 2020 | -56,000.00 |
| Jun 30, 2020 | 26,000.00 |
| Mar 31, 2020 | 1.99 Mn |
| Dec 31, 2019 | -7.97 Mn |
| Sep 30, 2019 | 144,000.00 |
| Jun 30, 2019 | -41,000.00 |
| Mar 31, 2019 | 7,000.00 |
| Dec 31, 2018 | -2.56 Mn |
| Sep 30, 2018 | -40,000.00 |
| Jun 30, 2018 | -64,000.00 |
| Mar 31, 2018 | -63,000.00 |
| Dec 31, 2017 | -115,000.00 |
| Sep 30, 2017 | -3,000.00 |
| Jun 30, 2017 | -129,000.00 |
| Mar 31, 2017 | -1.45 Mn |
| Dec 31, 2016 | -1.40 Mn |
| Sep 30, 2016 | -40,000.00 |
| Jun 30, 2016 | 72,000.00 |
| Mar 31, 2016 | 251,000.00 |